Published in J Urol on December 01, 2009
Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol (2014) 3.64
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol (2010) 2.54
Risk-based prostate cancer screening. Eur Urol (2011) 1.64
The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome. Cancer (2013) 1.52
The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients. J Urol (2010) 1.50
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
Updating risk prediction tools: a case study in prostate cancer. Biom J (2011) 1.08
External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort. Asian J Androl (2012) 1.05
A simple decision analytic solution to the comparison of two binary diagnostic tests. Stat Med (2012) 0.98
Treatment of localized prostate cancer: when is active surveillance appropriate? Nat Rev Clin Oncol (2010) 0.96
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proc Natl Acad Sci U S A (2012) 0.91
Can Western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population? Yonsei Med J (2013) 0.85
Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators. J Biomed Inform (2015) 0.84
The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study. Asian J Androl (2016) 0.83
Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer. PLoS One (2012) 0.78
Prostate cancer risk prediction in a urology clinic in Mexico. Urol Oncol (2012) 0.78
Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator. J Urol (2014) 0.75
The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy. Prostate Cancer Prostatic Dis (2017) 0.75
The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting. Urol Oncol (2012) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol (2013) 6.79
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol (2004) 6.08
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet (2006) 5.65
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA (2013) 5.56
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol (2007) 4.59
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol (2007) 4.59
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med (2009) 4.16
Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol (2002) 4.13
Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med (2004) 4.09
Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med (2006) 4.09
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) (2008) 3.99
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst (2003) 3.73
Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (2010) 3.66
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol (2011) 3.53
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Contemporary diagnosis and management of renal angiomyolipoma. J Urol (2002) 3.41
Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol (2006) 3.39
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A (2010) 3.37
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res (2008) 3.35
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2013) 3.35
National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology (2006) 3.34
Differential adoption of laser prostatectomy for treatment of benign prostatic hyperplasia. Urology (2013) 3.31
Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst (2003) 3.19
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst (2008) 3.16
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. J Clin Oncol (2008) 3.14
Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA (2013) 3.08
Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer (2009) 3.03
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol (2007) 2.97
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol (2009) 2.94